Severe Influenza Trial of ARbidol
Key facts
- Who runs it
- Capital Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 200 people enrolled
- Started
- 18 Jan 2019
- Ended
- 17 Oct 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Arbidol
- Placebos
- Record updated
- 25 June 2025
Who can take part
- Age
- 16 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Hospitalized males or females with a positive antigen or PCR test for influenza virus infection
- Age ≥16 years at the time of signing Informed Consent Form
- Arterial oxygen saturation (SaO2)/ pulse oxygen saturation (SPO2) ≤94% in room air condition
- ≤ 7 days since symptom onset. The onset of symptoms is defined as either: Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature- ≥38℃); Time when the patient experiences at least one general or respiratory symptom
- Willingness to use contraception for 7 days after the end of treatment
Who cannot take part
- More than 3 consecutive doses of NAIs within 2 days before enrolment (including oseltamivir, zanamivir, peramivir)
- Physicians make a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely
- Any condition requiring renal replacement therapy
- Severe liver disease (Child-Pugh score ≥ C)
- A history of hypersensitivity to arbidol or oseltamivir (Tamiflu®)
- Patient refusal to accept invasive organ support treatment if needed
- Women who are pregnant (including a positive pregnancy test at enrolment), breastfeeding, or within 2 weeks post-partum; The following female subjects do not need to undergo a pregnancy test at enrolment: a. Postmenopausal (defined as cessation of regular menstrual periods for 2 years or more and confirmed by a follicle-stimulating hormone test) women. b. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation
- Currently or have been involved in another anti-influenza treatment trial in the last 28 days
- Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, randomised, double-blind, controlled study to assess the efficacy and safety of arbidol plus oseltamivir, compared with oseltamivir alone in approximately 200 hospitalized adults and adolescent patients with confirmed severe influenza. Patients should be randomised as soon as possible after screening (no later than 12 hours), providing they are within 7 days of symptom onset. Patients will be assigned in a 1:1 ratio to receive an arbidol plus oseltamivir, or oseltamivir plus placebo. Rescreening of patients who fail to meet the inclusion and exclusion criteria will be permitted only once, providing the time from symptom onset to randomization is still within 7 days.
Read full original descriptionShow less
Arbidol/placebo will be administrated as 200mg TID from Days 1-7. Oseltamivir will be administered as 75mg twice daily from Days 1-7 (dose to be adjusted for renal impairment). Oseltamivir could be continued till influenza PCR negative. Both drugs, along with the corresponding placebo for arbidol, will be started at the time of randomization.
The 2 groups in the trial
- oseltamivir plus placeboExisting treatment, for comparison
Treatment: Placebos
- oseltamivir plus arbidolTreatment being tested
Treatment: Arbidol
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Oseltamivir and Arbidol Combination Antiviral Therapy Versus Oseltamivir Monotherapy for the Treatment of Severe influenza: a Multicentre, Double-blind, Randomised Phase 3 Trial
- Record updated
- 25 June 2025